Tetraphase Pharmaceuticals Inc. (TTPH)

0.32
NASDAQ : Health Technology
Prev Close 0.33
Day Low/High 0.31 / 0.34
52 Wk Low/High 0.23 / 3.21
Avg Volume 593.20K
Exchange NASDAQ
Shares Outstanding 54.32M
Market Cap 17.72M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals (TTPH) Is Today's Strong On High Volume Stock

Tetraphase Pharmaceuticals (TTPH) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a strong on high relative volume candidate

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Pharmaceuticals (TTPH) Strong On High Relative Volume Today

Tetraphase Pharmaceuticals (TTPH) Strong On High Relative Volume Today

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a strong on high relative volume candidate

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

4 Momentum Stocks Breaking Out and Poised to Move Higher

4 Momentum Stocks Breaking Out and Poised to Move Higher

Buy these four momentum stocks for strong gains over the next several months.

Tetraphase Pharmaceuticals (TTPH) Weak On High Volume

Tetraphase Pharmaceuticals (TTPH) Weak On High Volume

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a weak on high relative volume candidate

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Failed Bounce Brings Selling Pressure

Oil prices and energy funds slide.

Short Interest In Tetraphase Pharmaceuticals Increases 25.4%

Short Interest In Tetraphase Pharmaceuticals Increases 25.4%

The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, which shows a 552,149 share increase in total short interest for Tetraphase Pharmaceuticals, Inc , to 2,727,787, an increase of 25.38% since 03/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Tetraphase Pharmaceuticals Presents Detailed Results From Phase 3 Trials Of Eravacycline At 25th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

Tetraphase Pharmaceuticals Presents Detailed Results From Phase 3 Trials Of Eravacycline At 25th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

Late Breaker and Oral Presentations Support Eravacycline's Potential as a New IV/Oral Antibiotic Treatment for Multidrug-Resistant Infections

First Week of TTPH August 21st Options Trading

First Week of TTPH August 21st Options Trading

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the August 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 143 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

'Mad Money' Lightning Round: We're Staying Away From Adobe

'Mad Money' Lightning Round: We're Staying Away From Adobe

Cramer says to buy Berkshire Hathaway and wait on Rocket Fuel.

Tetraphase Pharmaceuticals Reports Fourth-Quarter And Full-Year 2014 Financial Results

Tetraphase Pharmaceuticals Reports Fourth-Quarter And Full-Year 2014 Financial Results

Company to Host Conference Call at 4:30 p.m. ET Today

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

When to take profits is a tricky but important decision.

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Fibrocell Science and Prothena have several 'shots on goal.'

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

TheStreet Quant Rating: D- (Sell)